This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Rosetta Genomics Announces Acceptance For Publication By Molecular Cancer Of Rosetta Cancer Origin Test Manuscript

Stocks in this article: ROSG

PHILADELPHIA and REHOVOT, Israel, June 6, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a manuscript reporting data validating the clinical utility of the Rosetta Cancer Origin Test (formerly miRview ® mets 2) to identify the tumor of origin in Cancer of Unknown or Uncertain Primary (CUP) has been accepted for publication in the peer-reviewed on-line journal Molecular Cancer. The article, titled "Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary," represents the seventh peer-reviewed publication relating to our CUP assays, and the fifth peer-reviewed publication relating to post market validation studies demonstrating the Cancer Origin Test's ability to identify tumor origin in CUP with 92% concordance, the highest level of accuracy of any similar study published to date.

The manuscript discusses the performance of the Cancer Origin Test, an assay utilizing 64 microRNAs to identify 42 tumor types, in formalin-fixed paraffin-embedded (FFPE) samples from 84 CUP patients The results showed concordance with the final diagnosis in 92% of patients; representing an improvement in agreement of 22 percentage points from presentation diagnosis to final diagnosis, which final diagnosis was  achieved after more precise clinical and pathological data was added to the data relied upon for the patient's initial assessment.

"MicroRNAs are particularly well-suited as biomarkers for identifying tumor origin as their expression levels and profile reflects tissue origin.  Importantly, microRNAs have been shown to be highly stable in tissue blocks, the most common and readily available specimen type in pathology. Profiling microRNA from FFPE tissue has been described to be superior to mRNA profiling, since the latter are prone to extensive degradation in FFPE samples," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.  "These data are important as they continue to confirm the clinical utility and extremely high level of concordance with the final diagnosis in real-world CUP patients.  The availability and accuracy of our Cancer Origin Test underscores why the uncertainty of CUP is no longer acceptable."

According to E. Robert Wassman, MD, FAAP, FACMG, Rosetta Genomics' Chief Medical Officer, "CUP presents clinicians with a diagnostic as well as a management challenge. The identification of tumor origin in metastatic patients is crucial for planning patient management and care, since many oncology treatments include cancer-specific therapies. Moreover, these specific therapies and related targeted therapies have been shown to lead to increased survival of patients with advanced cancers of known origin.  Consequently, it is not a matter of whether to use microRNA profiling, but when to use it."

About Rosetta Cancer Testing Services (formerly the miRview ® product line)Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma Test diagnoses mesothelioma, a cancer connected to asbestos exposure.  The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.  Rosetta's assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment.  In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test , 60,000 from the Rosetta Mesothelioma Test , 65,000 from the Rosetta Kidney Cancer Test and 226,000 patients from the Rosetta Lung Cancer Test . The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta GenomicsRosetta develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.  Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement DisclaimerVarious statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's development or commercialization of molecular diagnostics, the market acceptance of Rosetta's cancer testing services, particularly the Rosetta Cancer Origin Test™, Rosetta's capitalization of its microRNA platform, Rosetta's patent position and Rosetta's development of personalized medicine products and services constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact:   Rosetta Genomics  Ken Berlin, President & CEO (215) 382-9000, ext. 326  investors@rosettagenomics.com

Investor Contacts:  LHA    Anne Marie Fields(212) 838-3777 afields@lhai.com  or Bruce Voss(310) 691-7100 bvoss@lhai.com

SOURCE Rosetta Genomics Ltd.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs